Back to School: How biopharma can reboot drug development. Access exclusive analysis here


Momentum (read:fickle) and growth oriented funds that played a big part in driving up the market in the first quarter have had their heads in the sand of late. "They got spooked when their investments took a dive," during the summer sell-off, said Mitch Silber, partner at The Carson Group. "After Labor Day, when there was a resurgence, institutions with a momentum or growth focus for the most part didn't participate."

EASED-IN: EASDAQ is up and running, trading the securities of four European high-tech companies. The quartet includes Innogenetics,a Belgian biotech company that

Read the full 939 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers